Evom AI Inc.

Based in South Korea, Evom AI Inc. specializes in revolutionizing cardiovascular diagnostics through artificial intelligence, providing innovative solutions that enhance accuracy and efficiency in patient care. Evom AI Inc. was founded in 2025 in Seoul, South Korea, focusing on advanced technologies for cardiovascular care.

The company operates as an independent entity and has completed one deal to date. The company raised its initial funding in January 2026, securing Seed funding from Klim Ventures. Evom AI specializes in advanced cardiovascular care technology that utilizes artificial intelligence to close diagnostic gaps. Central to their offerings is a suite of AI-powered solutions designed to enhance the efficiency and accuracy of cardiovascular diagnostics.

Their flagship products automate echocardiography measurements, enabling rapid assessment of 30-60 echo parameters in seconds, while also detecting critical ECG findings. These solutions integrate multimodal data from echocardiography, ECG, and clinical records, providing clinicians with comprehensive cardiovascular risk assessments and decision support in a single view. Evom AI caters to healthcare providers, including hospitals and clinics, primarily in North America, Europe, and Asia, thereby expanding their impact across various geographical markets. Evom AI generates revenue primarily through partnerships and subscription models with healthcare institutions and providers.

By offering their AI solutions as a subscription service, hospitals can access real-time insights and diagnostic support while benefiting from ongoing updates and enhancements. The company structures transactions around its core products, which may include automated echocardiography and ECG analysis tools, allowing clients to streamline their cardiovascular care processes. Additionally, revenue may be derived from collaborations with healthcare organizations for regulatory submissions and market access services. Specific pricing plans for these services are tailored to the needs of individual clients, ensuring a customizable approach that meets diverse healthcare demands.

In January 2026, Evom AI Inc. raised an undisclosed amount of Seed funding from Klim Ventures. The company plans to use this funding to commercialize its artificial intelligence solution, aiming to expand its product offerings and enhance its market reach. Future initiatives will focus on launching new cardiovascular diagnostic tools and expanding into additional markets, particularly targeting growth in North America and Europe by the end of 2026.